1. "2017"
  2. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Journal Article (121)
  2. Meeting Abstract (86)
  3. Book Section (3)
  4. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (211)
  2. Executive Committee, Center for Hematologic Malignancies (211)
  3. Department of Medicine (173)
  4. Hematologic Malignancies, Division of (170)
  5. GSK Faculty (163)
  6. Tow Center for Developmental Oncology (TCDO) (102)

More Groups

People
  1. Anas Younes (45)
  2. Omar Abdel-Wahab (38)
  3. Ross Levine (38)
  4. Marcel Van Den Brink (36)
  5. Elli Papaemmanuil (21)
  6. Andrew Zelenetz (17)

More People

Years
  1. 2017 (211)
Publications
  1. Blood (68)
  2. Biology of Blood and Marrow Transplantation (10)
  3. Hematological Oncology (8)
  4. Haematologica (6)
  5. Journal of Clinical Oncology (6)
  6. Bone Marrow Transplantation (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. Nature Publishing Group (21)
  3. Elsevier Inc. (16)
  4. American Association for Cancer Research (10)
  5. Cell Press (9)
  6. Oxford University Press (8)

More Publishers

Results (211)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Graft-versus host disease (GVHD status and severity mediate late effects of allogeneic hematopoietic stem cell transplantation (HSCT) in a 1-year landmark analysis
    Meeting Abstract

    Sola, M.; Devlin, S. M.; Maloy, M.; Dierov, D.; Barker, J. N.; Castro-Malaspina, H.; Dahi, P.; Jakubowski, A. A.; Koehne, G.; Papadopoulos, E. B.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • CMV seropositivity and viremia drive T-cell reconstitution after CD34-selected allogeneic HCT
    Meeting Abstract

    Cho, C.; Hilden, P.; Politikos, I.; Borrill, T.; Ciolino, C.; Devlin, S. M.; Maloy, M.; Smith, K.; Giralt, S. A.; O'Reilly, R. J.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Combining the disease risk index (DRI) and hematopoietic cell transplantation comorbidity index (HCT-CI) provides a comprehensive prognostic model for CD34-selected allogeneic HCT
    Meeting Abstract

    Cho, C.; Hilden, P.; Avecilla, S. T.; Barker, J. N.; Castro-Malaspina, H.; Giralt, S. A.; Jakubowski, A. A.; Koehne, G.; Maloy, M.; Meagher, R.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • ABVD
    Book Section

    Younes, A.
    In Schwab, M. (Eds.) Encyclopedia of Cancer. 4th ed (2017)

    Fulltext@MSK | Save
  • Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
    Journal Article

    Abida, W.; Armenia, J.; Gopalan, A.; Brennan, R.; Walsh, M.; Barron, D.; Danila, D.; Rathkopf, D.; Morris, M.; Slovin, S.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate
    Meeting Abstract

    Wasserman, I.; Lee, L. H.; Shia, J. R.; Wu, C.; Chen, X.; Guillem, J. G.; Paty, P.; Weiser, M. R.; Nash, G. M.; Temple, L. K. F.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • The immunomodulatory protein Dickkopf-1 (DKK1) defines a non-neuroendocrine subtype of metastatic castration-resistant prostate cancer (mCRPC) with low AR and low PSA expression
    Meeting Abstract

    Wise, D.; Armenia, J.; Chen, Y.; Nelson, P.; Schultz, N.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Ten-year follow-up of pentostatin combined with cyclophosphamide, and rituximab in previously untreated indolent B-cell lymphoma
    Meeting Abstract

    Khashab, T.; Niaz, M. O.; Hagemeister, F. B.; Romaguera, J. E.; Fanale, M. A.; Pro, B.; McLaughlin, P.; Rodriguez, M. A.; Neelapu, S. S.; Fayad, L.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Safety and efficacy of atezolizumab in combination with obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma: An interim analysis
    Meeting Abstract

    Younes, A.; John, B. M.; Diefenbach, C. S.; Ferrari, S.; Kahn, C.; Sharman, J. P.; Tani, M.; Ujjani, C. S.; Vitolo, U.; Yuen, S.; more...
    Blood (2017)

    Fulltext@MSK | Save